Physician profile
Donna Rolin
NPI 1609002575
$3,098.22
in general payments reported to CMS, 2019-2025
13 companies · $14.10 in 2025
The $14.10 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $94.30 · 2022: $1,122 · 2023: $834 · 2024: $1,034 · 2025: $14.10.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,882.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,882.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $616.37 | 2021-2024 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $501.39 | 2022-2024 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Alkermes, INC. | $432.51 | 2022-2025 | Aristada, Lybalvi |
| Abbvie INC. | $287.17 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $230.74 | 2022-2023 | |
| Biogen, INC. | $189.82 | 2022-2024 | |
| Teva Pharmaceuticals USA, INC. | $159.10 | 2022-2024 | Austedo Xr |
| Janssen Pharmaceuticals, INC | $140.55 | 2023 | Invega Sustenna |
| Sunovion Pharmaceuticals INC. | $139.21 | 2022 | |
| Corium, LLC | $125.00 | 2024 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $105.05 | 2021-2024 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $86.69 | 2023 | Trintellix |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $84.62 | 2024 | Abilify Asimtufii |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Rolin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.